Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
基本信息
- 批准号:9330829
- 负责人:
- 金额:$ 53.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-15 至 2019-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddressAdverse eventAffectAreaBehaviorBenefits and RisksCessation of lifeDataDrug CombinationsDrug Metabolic DetoxicationDrug usageEducationEffectivenessEffectiveness of InterventionsEmergency SituationFrequenciesFriendsFundingGrantHarm ReductionHealthHealth PersonnelHeroinHeroin UsersImprisonmentIncentivesIndividualInjectableInstructionInterventionInvestigationKnowledgeLocationMeasuresMedicalMental HealthMethodsModificationNaloxoneNarcotic AntagonistsNeedle-Exchange ProgramsNeighborhoodsNew York CityOpioidOutcomeOutcome MeasureOverdoseParticipantPatient Self-ReportPatternPersonsPharmaceutical PreparationsPoisoningPopulationPremature MortalityPrevalencePreventionPrevention programProspective StudiesPublic HealthRandomizedRecording of previous eventsRecruitment ActivityReportingResearchResuscitationRetrospective StudiesReview LiteratureRisk AssessmentSafetySedation procedureServicesSiteSodium ChlorideSpousesSymptomsTechniquesTimeTrainingTraining ProgramsTraining and EducationVentilatory DepressionWaterexperiencefollow-upheroin overdosehigh riskillicit drug useimprovedmortalitynovelnovel strategiesopioid abuseopioid useoverdose deathoverdose preventionprescription opioidprogramsprospectivepsychosocialpublic health relevanceresponsesubstance abusertreatment as usual
项目摘要
DESCRIPTION (provided by applicant): Heroin overdose is the leading cause of premature mortality among heroin users (Smyth et al., 2007), and is the second most common drug responsible for poisoning deaths in New York City. Although deaths due to unintentional drug overdose decreased overall by 24% in NYC between 2005 and 2009, prescription opioid deaths increased by 20% during this same time period (Epi Data Brief, New York City Department of Health and Mental Hygiene (NYC DOHMH), 2011). A new harm reduction approach attempts to decrease opioid overdose by educating users in recognizing its symptoms and in using naloxone to reverse opioid-induced respiratory depression. In the proposed studies, we will attempt to obtain data on the impact that these programs may have on the health and outcomes of a population of opioid users at high risk for witnessing and experiencing an opioid overdose. We have preliminary evidence supporting the need for modifications of existing training programs to improve accurate identification of opioid overdose. Furthermore, a review of the literature has revealed that more extensive research, including proactive, long-term follow-up, is needed to better identify all of the benefits and risks associated with this approach. Specifically our investigation will recruit ongoing and recently detoxified opioid abusers from several sites throughout the NYC area. All participants will receive standard opioid overdose education training and naloxone to carry should they witness another person experiencing an overdose, or overdose themselves. One-third of the participants will be randomized to receive additional in-depth psychosocial education focusing on recognition and prevention of opioid overdose, and appropriate use of naloxone. Another one-third of the participants will receive the extensive training and be required to engage a spouse, partner, relative, or friend in this supplementary intervention. We expect that these psychosocial interventions (extensive training and training of a significant other) will improve overdose outcome measures. We also expect that the occurrence of naloxone-related adverse events will be minimal, and that access to naloxone will not significantly alter drug use patterns. The results of this study should provide one of the firs prospective and systematic assessments of the risks and benefits of this novel practice in the U.S., and educate the field on how we may improve upon current practices. In addition to conducting a prospective study, we also propose to conduct a retrospective analysis of the overall impact of overdose education and training in the use of naloxone by examining data collected by the NYC DOHMH. Specifically, both fatal and non-fatal opioid overdose rates will be compared in neighborhoods with facilities that offer overdose prevention training and naloxone to those that do not. We anticipate that the prevalence of fatal opioid overdose will be significantly lower in neighborhoods where opioid overdose prevention training and naloxone are offered.
描述(由申请人提供):海洛因过量是海洛因使用者过早死亡的主要原因(Smyth等,2007),并且是纽约市中毒死亡中毒的第二大药物。尽管在2005年至2009年期间,纽约市纽约市因无意药过量造成的死亡人数降低了24%,但在同一时期,处方阿片类药物的死亡人数增加了20%(EPI数据摘要,纽约市卫生与精神卫生部(NYC DOHMH),2011年,2011年)。一种新的危害减少方法试图通过教育用户识别其症状并使用纳洛酮来逆转阿片类药物诱导的呼吸道抑郁,从而减少阿片类药物过量。在拟议的研究中,我们将尝试获取有关这些计划可能对目击和体验阿片类药物过量风险的阿片类药物使用者的健康和结果的影响的数据。我们有初步证据,支持对现有培训计划进行修改,以改善阿片类药物过量的准确识别。此外,对文献的回顾表明,需要更广泛的研究,包括积极的长期随访,以更好地确定与这种方法相关的所有好处和风险。具体来说,我们的调查将招募来自纽约市多个地点的正在进行的和最近排毒的阿片类药物滥用者。所有参与者将接受标准的阿片类药物过量教育培训和纳洛酮,如果他们亲眼目睹另一个人过量或过量服用的人。三分之一的参与者将被随机分配,以接受额外的深入的社会心理教育,重点是识别和预防阿片类药物过量,并适当使用纳洛酮。另外三分之一的参与者将接受广泛的培训,并被要求与配偶,伴侣,亲戚或朋友一起参加这种补充干预。我们预计这些社会心理干预措施(对他人的广泛培训和培训)将改善过量的结果指标。我们还期望与纳洛酮相关的不良事件的发生将是最小的,并且获得纳洛酮不会显着改变药物使用模式。这项研究的结果应为美国新颖实践的风险和好处提供FIR的预期和系统评估之一,并就我们如何改善当前实践进行教育。除了进行一项前瞻性研究外,我们还建议通过检查纽约DOHMH收集的数据,对过量教育和培训在使用纳洛酮中的总体影响进行回顾性分析。具体而言,将比较致命的和非致命的阿片类药物过量率,这些设施提供了预防过量培训的设施,而纳洛酮则将与那些不提供过量的纳洛酮进行比较。我们预计,在提供阿片类药物预防训练和纳洛酮的社区中,致命阿片类药物过量的患病率将大大降低。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANDRA D COMER其他文献
SANDRA D COMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANDRA D COMER', 18)}}的其他基金
Transcutaneous Phrenic Nerve Stimulation for Treating Opioid Overdose
经皮膈神经刺激治疗阿片类药物过量
- 批准号:
10681111 - 财政年份:2023
- 资助金额:
$ 53.42万 - 项目类别:
Phase 1 and 2 studies of sublingual dexmedetomidine, an alpha 2 adrenergic agonist, for treating opioid withdrawal
舌下含服右美托咪定(一种 α2 肾上腺素能激动剂)用于治疗阿片类药物戒断的 1 期和 2 期研究
- 批准号:
10478324 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别:
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
开发逆转芬太尼及其类似物过量的单克隆抗体:从制造到临床试验
- 批准号:
10615519 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别:
Development of ITI-333, a μ-opioid Receptor Partial Agonist and 5HT2A and D1 Receptor Antagonist, for the Treatment of Opioid Use Disorders
开发 ITI-333,一种 μ-阿片受体部分激动剂和 5HT2A 和 D1 受体拮抗剂,用于治疗阿片类药物使用障碍
- 批准号:
9841388 - 财政年份:2019
- 资助金额:
$ 53.42万 - 项目类别:
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components
多价阿片类疫苗成分的 1a/1b 期临床试验
- 批准号:
10782616 - 财政年份:2018
- 资助金额:
$ 53.42万 - 项目类别:
CERC-501 Kappa Antagonist for Nicotine Dependence
CERC-501 尼古丁依赖性 Kappa 拮抗剂
- 批准号:
9041849 - 财政年份:2016
- 资助金额:
$ 53.42万 - 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
- 批准号:
9066619 - 财政年份:2015
- 资助金额:
$ 53.42万 - 项目类别:
Dynamic Contrast-Enhanced MRI to Measure Blood-Brain Barrier Permeability in Substance Abusers
动态对比增强 MRI 测量药物滥用者的血脑屏障渗透性
- 批准号:
8989439 - 财政年份:2015
- 资助金额:
$ 53.42万 - 项目类别:
Risk and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
过量教育和向海洛因使用者开纳洛酮处方的风险和益处
- 批准号:
8694865 - 财政年份:2014
- 资助金额:
$ 53.42万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
与阿片类药物使用障碍药物相关的口腔并发症的风险比较:混合方法
- 批准号:
10765049 - 财政年份:2023
- 资助金额:
$ 53.42万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10437438 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别:
A novel data-driven approach for personalizing smoking cessation pharmacotherapy
一种新的数据驱动的个性化戒烟药物治疗方法
- 批准号:
10578721 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别:
Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trial
氯胺酮在急诊科治疗酒精使用障碍:一项双盲、安慰剂对照随机临床试验
- 批准号:
10593244 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别:
Limbic Pallidum DBS for the treatment of severe alcohol use disorder
边缘苍白球 DBS 用于治疗严重酒精使用障碍
- 批准号:
10539383 - 财政年份:2022
- 资助金额:
$ 53.42万 - 项目类别: